Cerity Partners’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Cerity Partners’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-4,194	Closed	-$485K	–	1910
2023 Q3	$485K	Sell	4,194 -2,906	-41%	-$312K	﹤0.01%	989
2023 Q2	$730K	Buy	7,100 +578	+9%	+$61K	﹤0.01%	1030
2023 Q1	$7.19M	Sell	6,522 -1,247	-16%	-$138K	0.02%	423
2022 Q4	$884K	Buy	7,769 +1,906	+33%	+$158K	0.01%	729
2022 Q3	$363K	Buy	+5,863	New	+$410K	﹤0.01%	829

Other funds holding HZNP

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Cerity Partners's HZNP Position: Q4 2023 in Review

Cerity Partners sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 4,194 shares — an estimated $485K sold.

Cerity Partners first reported a position in HZNP in Q3 2022 and held it in 5 quarters. The position peaked at $7.19M in Q1 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

Cerity Partners reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Cerity Partners sold 4,194 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $485K.
Cerity Partners first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2022 and held it in 5 quarters.
Cerity Partners's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $7.19M in Q1 2023.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Cerity Partners's 13F filing for Q4 2023, filed 26 Jan 2024.